Tiziana rises on positive data from preclinical study on lead drug

Tiziana Life Sciences

04/04/2023 13:15

** Shares of drug developer Tiziana Life Sciences Ltd  TLSA.O  rise 8.4% to $1.1 premarket 
    ** Co says its lead drug candidate, intranasal foralumab, shows beneficial effect in
hemorrhagic stroke after one month of treatment in a preclinical study 
    ** Hemorrhagic stroke is a life-threatening medical condition caused when a blood vessel in
the brain ruptures and bleeds   
    ** Intranasal foralumab appears to have beneficial effect in controlling inflammation in the
brain by introducing immune cells called regulatory T cells -TLSA  
    ** Stock up ~70% so far this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))